Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
Date:5/16/2013

SAN FRANCISCO, May 16, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 21, 2013 at 10:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted in the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until June 22, 2013.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:
Jennifer Ruddock /Nektar Therapeutics
(415) 482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2019)... ... ... life has been saved thanks to the expert care of Sheba Medical Center, Tel HaShomer. ... her was once rescued by her family when he was attacked by a vicious crowd ... son and made a wrong turn into a Palestinian village near Ramallah. An angry mob ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... announced today that it has partnered with ZRx Outcomes Research Inc. to ... research, systematic literature review, comparative effectiveness research (CER), decision modeling, dossier development ...
(Date:3/20/2019)... ... March 20, 2019 , ... NDA Partners Chairman Carl ... extensive experience in the development of generic drugs and drug/device combination products at FDA ... an Expert Consultant. , During his career with FDA, Mr. Gonitzke served as Senior ...
Breaking Medicine Technology:
(Date:3/20/2019)... ... March 20, 2019 , ... EBSCO Health ... decision aids, has announced the certification of two decision aids by the Washington ... Down Syndrome Screening Test: Yes or No? Currently, Washington is the only state ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... Atlanta, has some advice for financial consultants: “Learn to practice mindfulness.” , ... in Financial Advisor magazine, Dr. Lowrance writes that financial advisors are discovering the ...
(Date:3/20/2019)... (PRWEB) , ... March 20, 2019 , ... ... today a new service, CardioCHECK a new way to diagnose cardiac arrhythmias in ... diagnose patients with cardiac arrythmias by utilizing mobile cardiac telemetry (MCT) in the ...
(Date:3/20/2019)... ANGELES (PRWEB) , ... March 20, 2019 , ... AutismOne ... from fiction in the current debate over measles. Dr. Wakefield's presentation at the AutismOne ... regard to both the pre-vaccine and vaccine eras. The lecture will examine the consequences ...
(Date:3/20/2019)... , ... March 20, 2019 , ... Caring.com, the nation’s ... top medical alert systems for 2019. The medical alert provider was recognized as the ... companies that qualified for the list based on its demonstration of excellent customer service, ...
Breaking Medicine News(10 mins):